Pages that link to "Q35880368"
Jump to navigation
Jump to search
The following pages link to Efficacy and safety of tiotropium in COPD patients in primary care--the SPiRiva Usual CarE (SPRUCE) study. (Q35880368):
Displaying 35 items.
- Tiotropium versus placebo for chronic obstructive pulmonary disease (Q24194833) (← links)
- Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis (Q24197853) (← links)
- Tiotropium versus placebo for chronic obstructive pulmonary disease (Q24202175) (← links)
- Tiotropium for stable chronic obstructive pulmonary disease (Q24246991) (← links)
- Comorbidities of patients in tiotropium clinical trials: comparison with observational studies of patients with chronic obstructive pulmonary disease (Q26823339) (← links)
- Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis (Q30620671) (← links)
- Evidence synthesis for count distributions based on heterogeneous and incomplete aggregated data. (Q30949429) (← links)
- Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis (Q33698524) (← links)
- Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review (Q34957303) (← links)
- Information for physicians and pharmacists about drugs that might cause dry mouth: a study of monographs and published literature (Q35057288) (← links)
- Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial (Q35695190) (← links)
- Diagnosis of COPD and clinical course in patients with unrecognized airflow limitation (Q36789935) (← links)
- SOSPES: SPIRIVA® observational study measuring SGRQ score in routine medical practice in Central and Eastern Europe (Q37249775) (← links)
- Tiotropium HandiHaler in the treatment of COPD: a safety review (Q37474538) (← links)
- Safety and pharmacological profile of tiotropium bromide. (Q37510963) (← links)
- Efficacy of tiotropium in the prevention of exacerbations of COPD. (Q37555782) (← links)
- New developments in the assessment of COPD: early diagnosis is key. (Q37616657) (← links)
- Earlier diagnosis and earlier treatment of COPD in primary care. (Q37792835) (← links)
- Pharmacotherapies for chronic obstructive pulmonary disease: a multiple treatment comparison meta-analysis (Q37864538) (← links)
- NVA237, a long-acting muscarinic antagonist, as an emerging therapy for chronic obstructive pulmonary disease (Q37867838) (← links)
- Tiotropium bromide inhalation powder: a review of its use in the management of chronic obstructive pulmonary disease (Q37973132) (← links)
- Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression (Q38317463) (← links)
- Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease (Q38388302) (← links)
- Long-acting muscarinic antagonists (Q38537326) (← links)
- Tiotropium formulations and safety: a network meta-analysis (Q39137733) (← links)
- Comparative efficacy of long-acting bronchodilators for COPD: a network meta-analysis (Q39399389) (← links)
- Long-term outcomes in chronic obstructive pulmonary disease patients: exploring the effects of inhalatory devices and their influence on the outcome (Q40706819) (← links)
- Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium (Q42533804) (← links)
- Pharmacoeconomic evaluation of tiotropium bromide in the long-term treatment of chronic obstructive pulmonary disease (COPD) in Italy (Q45770612) (← links)
- Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. (Q45917632) (← links)
- Collection, synthesis, and interpretation of evidence: a proof-of-concept study in COPD. (Q51278385) (← links)
- Long-term safety of tiotropium/olodaterol Respimat® in patients with moderate-to-very severe COPD and renal impairment in the TONADO® studies. (Q55133367) (← links)
- What have we learned from observational studies and clinical trials of mild to moderate COPD? (Q57777296) (← links)
- Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis (Q57817177) (← links)
- Revefenacin: A Once-Daily, Long-Acting Bronchodilator For Nebulized Treatment Of COPD (Q92460821) (← links)